Development of the ^99mTc-Labelled SST₂ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

• Үндсэн зохиолчид: Doroteja Novak (Зохиогч), Barbara Janota (Зохиогч), Anton Amadeus Hörmann (Зохиогч), Agnieszka Sawicka (Зохиогч), Marko Kroselj (Зохиогч), Alicja Hubalewska-Dydejczyk (Зохиогч), Melpomeni Fani (Зохиогч), Renata Mikolajczak (Зохиогч), Petra Kolenc (Зохиогч), Clemens Decristoforo (Зохиогч), Piotr Garnuszek (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2023-03-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Broad availability and cost-effectiveness of ⁹⁹Mo/^99mTc generators worldwide support the use, and thus the development, of novel ^99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroe...